Octave Bioscience
PrivateLast Round
Series C
Sep 4, 2025
Total Funding Raised
$139.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Octave Bioscience operates in Healthcare & Life Sciences and is based in Menlo Park, California. Its latest recorded funding round was a Series C round in September 2025.
Octave Bioscience is a healthcare technology company that develops a clinical platform to generate, analyze, and integrate data for advancing care in multiple sclerosis and other neurodegenerative diseases while optimizing medication use and reducing overall healthcare costs.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Octave Bioscience Comparables
Compare Octave Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Progentec Diagnostics | 76% | |
| Amprion | 70% | |
| GLX Analytix | 70% |
For institutional investors. Book with your work email.
Octave Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 4, 2025 | ||||
| Debt | Sep 4, 2025 | ||||
| Grant | Nov 15, 2023 | ||||
| Series B Extension | Jul 26, 2023 | ||||
| Series B | Dec 17, 2020 | ||||
Series A | Jul 12, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Octave Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| dRx Capital | Series B Extension |
| S32 | Series B Extension, Series C, Series A, Series B |
| Deerfield Management | Series B Extension, Series B |
| dRx Capital | Series B Extension |
| Blue Cross Blue Shield Association | Series B, Series A |
| Valhalla Foundation | Series C |
| Intermountain Ventures | Series B Extension, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 106% MoM, reaching 7.2K.
- Jan 8, 2026
Kirk Stockwood appointed as new Senior Vice President, Commercial.
For institutional investors. Book with your work email.
Octave Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Octave Bioscience's valuation, stock price, and market status.
Is Octave Bioscience a public or private company?
Octave Bioscience is a private company.
What is the current stock price of Octave Bioscience?
Octave Bioscience is a private company, so its shares have no public market price. Caplight tracks Octave Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Octave Bioscience worth (valuation)?
Valuation information for Octave Bioscience is not publicly available.
Can I buy Octave Bioscience stock?
Octave Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Octave Bioscience's last funding round?
Octave Bioscience's most recent funding round was Series C on September 4, 2025.
Who are the main investors in Octave Bioscience?
Key investors in Octave Bioscience include Blue Cross Blue Shield Association, Northpond Ventures, Northpond Ventures, Blue Venture Fund.
Will Octave Bioscience IPO soon?
No public IPO plans have been announced for Octave Bioscience.
How can I track Octave Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Octave Bioscience's shares on secondary markets.